ReviewBiologics : targets & therapy2023
Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer.
Review in Biologics : targets & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Exosomes and Triple-Negative Breast Cancer: Current Knowledge and Clinical Significance.International journal of molecular sciences · 2026Pooled it
- Triple-Negative Breast Cancer Cells Utilize IL8 and CXCL1 to Suppress NK Cells' Function and Facilitate Cancer Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Beyond chemotherapy: the evolving role of photodynamic therapy in triple-negative breast cancer.Medical oncology (Northwood, London, England) · 2026Review
- Cannabidiol potentiates olaparib-induced cytotoxicity through cell cycle arrest and DNA damage modulation in breast cancer cells.Molecular and cellular biochemistry · 2026Article
- Bioactive Natural Compounds in Triple-Negative Breast Cancer: Molecular Targets and Therapeutic Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Targeting Triple-Negative Breast Cancer: A Special Focus on Phototherapy and Nanomaterials.Molecules (Basel, Switzerland) · 2026Review
- Causality between immune cells and HER2-breast cancer: A 2‑sample Mendelian randomization study.Medicine · 2026Article
- Integrative Computational and Transcriptional Analysis of NF-κB and HIF-1α Modulation Following Doxorubicin Treatment in Triple-Negative Breast Cancer Cells.Journal of experimental pharmacology · 2026Article
- Non-orthosteric inhibition of enolase 1 impedes growth of triple-negative breast cancer.Cell reports. Medicine · 2025Article
- Dissecting Morphological and Functional Dynamics of Non-Tumorigenic and Triple-Negative Breast Cancer Cell Lines Using PCA and t-SNE Analysis.Cancer reports (Hoboken, N.J.) · 2025Article
- Prognostic Significance and Molecular Classification of Triple Negative Breast Cancer: A Systematic Review.European journal of breast health · 2025Article
- ZMIZ2/MCM3 Axis Participates in Triple-Negative Breast Cancer Progression.Oncology research · 2025Article
- Opportunities and Challenges in the Development of Antibody-Drug Conjugate for Triple-Negative Breast Cancer: The Diverse Choices and Changing Needs.World journal of oncology · 2024Review
- Cutting-edge approaches for targeted drug delivery in breast cancer: beyond conventional therapies.Nanoscale advances · 2024Review
- Methylation of ESRα Promoters in Benign Breast Tumors Could Be a Signature for Progression to Breast Cancer in African American Women.Cancer genomics & proteomicsArticle
- Stage-specific biomarkers in triple-negative breast cancer: Preliminary findings from bioinformatics approaches.Cancer biomarkers : section A of Disease markersArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that is conventionally characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), accounting for approximately 15-20% of all breast cancers. Compared to other molecular phenotypes, TNBC is typically associated with high malignancy and poor prognosis. Cytotoxic agents have been the mainstay of treatment for the past few decades due to the lack of definitive targets and limited therapeutic interventions. However, recent developments have demonstrated that TNBC has peculiar molecular classifications and biomarkers, which provide the possibility of evolving treatment from basic cytotoxic chemotherapy to an expanding domain of targeted therapies. This review presents a framework for understanding the current clinical experience surrounding molecular biology mechanisms in TNBC (Figure 1). Including immunotherapy, polymerase (PARP) and PI3K/AKT pathway inhibitors, antibody-drug conjugates, and androgen receptor (AR) blockade. Additionally, the role of miRNA therapeutics targeting TNBC and potential strategies targeting cancer stem cells (CSCs) are discussed and highlighted. As more and more treatments arise on the horizon, we believe that patients with TNBC will have a new sense of hope.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.